港股异动 | 九源基因(02566)再涨超8% 吉立欣获国家药监局批准上市公司携手复星医药开拓全球市场

智通财经2025-07-21

智通财经APP获悉，九源基因(02566)再涨超8%，截至发稿，涨6.34%，报10.74港元，成交额672.52万港元。消息面上，九源基因本月初公告，马来酸阿伐曲泊帕片(商品名：吉立欣)已获国家药品监督管理局批准上市，适用于择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者；既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者，使血小板计数升高并减少...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2553440115?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-21 10:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553440115","market":"sh","top_or_hot":-1,"title":"港股异动 | 九源基因(02566)再涨超8% 吉立欣获国家药监局批准上市 公司携手复星医药开拓全球市场","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，九源基因(02566)再涨超8%，截至发稿，涨6.34%，报10.74港元，成交额672.52万港元。消息面上，九源基因本月初公告，马来酸阿伐曲泊帕片(商品名：吉立欣)已获国家药品监督管理局批准上市，适用于择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者；既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者，使血小板计数升高并减少...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1319902.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 九源基因(02566)再涨超8% 吉立欣获国家药监局批准上市 公司携手复星医药开拓全球市场</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 九源基因(02566)再涨超8% 吉立欣获国家药监局批准上市 公司携手复星医药开拓全球市场\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-21 10:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1319902.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，九源基因(02566)再涨超8%，截至发稿，涨6.34%，报10.74港元，成交额672.52万港元。消息面上，九源基因本月初公告，马来酸阿伐曲泊帕片(商品名：吉立欣)已获国家药品监督管理局批准上市，适用于择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者；既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者，使血小板计数升高并减少...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1319902.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1319902.html","article_id":"2553440115","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553440115","pubTimestamp":1753065915,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，九源基因再涨超8%，截至发稿，涨6.34%，报10.74港元，成交额672.52万港元。消息面上，九源基因本月初公告，马来酸阿伐曲泊帕片已获国家药品监督管理局批准上市，适用于择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者；既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症成人患者，使血小板计数升高并减少或防止出血。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","02196":"复星医药","BK0183":"MSCI概念","BK1191":"制药","BK0188":"融资融券","BK1515":"抗疫概念","BK0096":"民营医院","BK0239":"医药制造","BK1593":"医美概念股","BK0012":"证金概念","02566":"九源基因","BK0196":"行业龙头","BK0175":"白马股","BK0187":"一线龙头","BK0060":"抗癌","BK0028":"国家队"},"translate_title":"Changes in Hong Kong stocks | Jiuyuan Gene (02566) rose more than 8% Jilixin was approved by the State Food and Drug Administration as a listed company to join hands with Fosun Pharma to explore the global market","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1,"02566":1},"content_text":"智通财经APP获悉，九源基因(02566)再涨超8%，截至发稿，涨6.34%，报10.74港元，成交额672.52万港元。消息面上，九源基因本月初公告，马来酸阿伐曲泊帕片(商品名：吉立欣)已获国家药品监督管理局批准上市，适用于择期行诊断性操作或者手术的慢性肝病相关血小板减少症的成年患者；既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者，使血小板计数升高并减少或防止出血。值得注意的是，5月28日，据复星医药官微消息，近日，复星医药与九源基因就多款生物药及创新药械产品的海外独家商业化权益合作在杭州举办签约仪式。根据协议，复星医药获得九源基因的独家授权，就司美格鲁肽、骨优导和JY-23等产品，在中东北非、撒哈拉以南非洲全部国家及部分东盟国家的独家临床开发、注册、生产和商业化权益。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2553440115","isCrawlerRequest":true}

港股异动 | 九源基因(02566)再涨超8% 吉立欣获国家药监局批准上市 公司携手复星医药开拓全球市场

精彩评论

港股异动 | 九源基因(02566)再涨超8% 吉立欣获国家药监局批准上市公司携手复星医药开拓全球市场